<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A prompt distinction of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) versus diffuse large B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) has important clinical implications; however, this distinction can be difficult </plain></SENT>
<SENT sid="1" pm="."><plain>We analyzed 74 adult gray zone and 10 reference pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> using immunohistochemistry (Ki-67, CD10, bcl2, bcl6) and fluorescence in situ hybridization (FISH) for MYC, BCL2, and BCL6 breakpoints </plain></SENT>
<SENT sid="2" pm="."><plain>Two algorithms for classification were followed: algorithm A used a two-step review by four hemato-pathologists and algorithm B a set of only biologic markers (Ki-67 &gt; or = 90%, CD10+, bcl6+, bcl2-, MYC breakpoint+, BCL2 and BCL6 breakpoint-) </plain></SENT>
<SENT sid="3" pm="."><plain>Both algorithms categorized <z:hpo ids='HP_0000001'>all</z:hpo> reference cases as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In the adult group, algorithm A resulted in 21 adult <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and 52 DLBCL and algorithm B in 23 BL and 51 "non-Burkitt" <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (nBL); 9 cases (12%) contained two different translocations and were categorized as nBL in algorithm B </plain></SENT>
<SENT sid="5" pm="."><plain>Fifteen cases (20%) fulfilled the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> criteria of both algorithms </plain></SENT>
<SENT sid="6" pm="."><plain>Although not considered as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> according to both algorithms, many other <z:hpo ids='HP_0002665'>lymphomas</z:hpo> showed nonetheless a phenotypic and/or genetic shift to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> according to algorithm B was more homogeneous with respect to clinical presentation (gender and localization) than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> defined by algorithm A </plain></SENT>
<SENT sid="8" pm="."><plain>Our data suggest that only a few cases of these gray zone <z:hpo ids='HP_0002665'>lymphomas</z:hpo> represent true de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Immunohistochemistry for Ki-67, CD10, and bcl2 with analysis of MYC and preferably also BCL2 and BCL6 may be advised as a marker panel for this diagnostic dilemma </plain></SENT>
</text></document>